Full Text View
Tabular View
No Study Results Posted
Related Studies
Teicoplanin in Treating Septicemia in Patients Who Are Receiving Chemotherapy Through a Central Venous Catheter
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), June 2009
First Received: September 13, 2001   Last Updated: July 1, 2009   History of Changes
Sponsored by: Children's Cancer and Leukaemia Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00024453
  Purpose

RATIONALE: Giving the antibiotic teicoplanin by infusion and allowing bacteria to be exposed to the antibiotic for a longer period of time may be effective in preventing or controlling septicemia.

PURPOSE: Randomized clinical trial to compare two different methods of giving teicoplanin in treating septicemia in patients who are receiving chemotherapy through a central venous catheter.


Condition Intervention
Infection
Biological: teicoplanin

Study Type: Interventional
Study Design: Supportive Care, Randomized, Active Control
Official Title: The Use of Teicoplanin in the Treatment of Septicaemia Caused by Coagulase-Negative Staphylococci - A Randomized Study Comparing Bolus Injection With Infused and/or Line-Locked Teicoplanin

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 1360
Study Start Date: February 1999
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Compare the response and cure rate of coagulase-negative staphylococcal septicemia in patients receiving chemotherapy through a central venous catheter treated with 2 different schedules of teicoplanin.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and number of central venous catheter lumens

(1 vs 2). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive teicoplanin IV bolus every 12 hours for 3 doses and then once daily for 5 doses (total of 7 days).
  • Arm II: Patients receive teicoplanin IV over 2 hours and/or by antibiotic lock every 12 hours for 3 doses and then once daily for 5 doses (total of 7 days).

PROJECTED ACCRUAL: Approximately 490-1,360 patients will be accrued for this study within 2.2-6.2 years.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Suspected septicemia caused by coagulase-negative staphylococci
  • Single or double lumen (no triple lumen) central venous catheter (CVC) (including subcutaneous ports) that can be flushed and aspirated

    • Expected to remain in situ for at least 8 weeks
  • No coagulase-negative septicemia associated with existing CVC within the past 12 weeks
  • Receiving chemotherapy for neoplastic condition, aplastic anemia, Fanconi's anemia, Langerhans' cell histiocytosis, or myelodysplasia

PATIENT CHARACTERISTICS:

Age:

  • 2 months and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Creatinine clearance at least 60 mL/min

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00024453

Locations
Ireland
Our Lady's Hospital for Sick Children Crumlin Recruiting
Dublin, Ireland, 12
Contact: Fin Breatnach, MD, FRCPE     353-1-409-6659     fin.breatnach@olhsc.ie    
United Kingdom, England
Addenbrooke's Hospital Recruiting
Cambridge, England, United Kingdom, CB2 2QQ
Contact: Denise Williams, MD     44-1223-216-878        
Birmingham Children's Hospital Recruiting
Birmingham, England, United Kingdom, B4 6NH
Contact: Bruce Morland, MD     44-121-333-8233     bruce.morland@bch.nhs.uk    
Bristol Royal Hospital for Children Recruiting
Bristol, England, United Kingdom, BS2 8BJ
Contact: Annabel B.M. Foot     44-117-342-8520        
Children's Hospital - Sheffield Recruiting
Sheffield, England, United Kingdom, S10 2TH
Contact: Mary P. Gerrard, BSc, MBChB, FRCP, FRCPCH     44-114-271-7366     mary.gerrard@sch.nhs.uk    
Oxford Radcliffe Hospital Recruiting
Oxford, England, United Kingdom, 0X3 9DU
Contact: Kate Wheeler, MD     44-186-522-1066        
Leeds Cancer Centre at St. James's University Hospital Recruiting
Leeds, England, United Kingdom, LS9 7TF
Contact: Adam Glaser, MD     44-113-206-4984     adam.glaser@leedsth.nhs.uk    
Leicester Royal Infirmary Recruiting
Leicester, England, United Kingdom, LE1 5WW
Contact: Rosemary S. Shannon, MD     44-116-254-1414        
Newcastle Upon Tyne Hospitals NHS Trust Recruiting
Newcastle-Upon-Tyne, England, United Kingdom, NE7 7DN
Contact: Andrew David J. Pearson, MD, FRCP, DCh     44-191-232-5131 ext. 24101        
Great Ormond Street Hospital for Children Recruiting
London, England, United Kingdom, WC1N 3JH
Contact: Penelope Brock, MD, PhD     44-20-829-8832     Brockp@gosh.nhs.uk    
Queen's Medical Centre Recruiting
Nottingham, England, United Kingdom, NG7 2UH
Contact: David A. Walker     44-115-924-9924 ext 61727     david.walker@nottingham.ac.uk    
Royal Liverpool Children's Hospital, Alder Hey Recruiting
Liverpool, England, United Kingdom, L12 2AP
Contact: Heather P. McDowell, MD     44-151-293-3679        
Royal Manchester Children's Hospital Recruiting
Manchester, England, United Kingdom, M27 4HA
Contact: Bernadette Brennan, MD     44-161-922-2227     bernadette.brennan@cmmc.nhs.uk    
Royal Marsden - Surrey Recruiting
Sutton, England, United Kingdom, SM2 5PT
Contact: Kathy Pritchard-Jones, MD     44-20-8661-3452 ext 3498        
Saint Bartholomew's Hospital Recruiting
London, England, United Kingdom, EC1A 7BE
Contact: Judith E. Kingston, MD     44-20-7943-1339     j.e.kingston@qmul.ac.uk    
Southampton General Hospital Recruiting
Southampton, England, United Kingdom, SO16 6YD
Contact: Janice A. Kohler, MD, FRCP     44-23-8079-6942        
University College of London Hospitals Recruiting
London, England, United Kingdom, WIT 3AA
Contact: Maria Michelagnoli, MD     44-20-7380-9950     maria.michelagnoli@uclh.org    
United Kingdom, Northern Ireland
Royal Belfast Hospital for Sick Children Recruiting
Belfast, Northern Ireland, United Kingdom, BT12 6BE
Contact: Anthony McCarthy, MD     44-289-063-3631     anthonymcarthy@royalhospital.n.i.nhs.uk    
United Kingdom, Scotland
Aberdeen Royal Infirmary Recruiting
Aberdeen, Scotland, United Kingdom, AB25 2ZN
Contact: D.J. King, MD     44-84-5456-6000     derek.king@arh.gampian.scot.nhs.uk    
Royal Hospital for Sick Children Recruiting
Glasgow, Scotland, United Kingdom, G3 8SJ
Contact: E.M. Simpson     44-141-201-0000        
Royal Hospital for Sick Children Recruiting
Edinburgh, Scotland, United Kingdom, EH9 1LF
Contact: W. Hamish Wallace, MD     44-131-536-0426        
Sponsors and Collaborators
Children's Cancer and Leukaemia Group
Investigators
Study Chair: Barry Pizer, MD Royal Liverpool Children's Hospital, Alder Hey
  More Information

Additional Information:
No publications provided

Study ID Numbers: CDR0000068944, CCLG-SC-1999-01, EU-20124
Study First Received: September 13, 2001
Last Updated: July 1, 2009
ClinicalTrials.gov Identifier: NCT00024453     History of Changes
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
infection

Study placed in the following topic categories:
Coagulase
Systemic Inflammatory Response Syndrome
Anti-Bacterial Agents
Sepsis
Teicoplanin
Inflammation

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Anti-Infective Agents
Anti-Bacterial Agents
Sepsis
Teicoplanin
Pathologic Processes
Therapeutic Uses
Infection
Pharmacologic Actions
Inflammation

ClinicalTrials.gov processed this record on July 02, 2009